JP6837992B2 - 非伝達性の抗生物質耐性を有し、同じ治療適応症を有する乳酸菌および/またはビフィズス菌の同時使用と組合せた、特定の治療活性を有する抗生物質の使用 - Google Patents
非伝達性の抗生物質耐性を有し、同じ治療適応症を有する乳酸菌および/またはビフィズス菌の同時使用と組合せた、特定の治療活性を有する抗生物質の使用 Download PDFInfo
- Publication number
- JP6837992B2 JP6837992B2 JP2017556688A JP2017556688A JP6837992B2 JP 6837992 B2 JP6837992 B2 JP 6837992B2 JP 2017556688 A JP2017556688 A JP 2017556688A JP 2017556688 A JP2017556688 A JP 2017556688A JP 6837992 B2 JP6837992 B2 JP 6837992B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lmg
- antibiotic
- strain
- bifidobacterium longum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims description 37
- 229940088710 antibiotic agent Drugs 0.000 title claims description 32
- 230000003115 biocidal effect Effects 0.000 title claims description 29
- 241000894006 Bacteria Species 0.000 title claims description 24
- 230000001225 therapeutic effect Effects 0.000 title claims description 16
- 241000186000 Bifidobacterium Species 0.000 title claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title description 8
- 235000014655 lactic acid Nutrition 0.000 title description 4
- 239000004310 lactic acid Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 43
- 241001608472 Bifidobacterium longum Species 0.000 claims description 26
- 206010012735 Diarrhoea Diseases 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 21
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 20
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 19
- 241001106955 bacterium W11 Species 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 13
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 229960003040 rifaximin Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 206010010774 Constipation Diseases 0.000 claims description 10
- 229930189077 Rifamycin Natural products 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 241000590002 Helicobacter pylori Species 0.000 claims description 8
- 229940037467 helicobacter pylori Drugs 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims description 6
- 229940081192 rifamycins Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 5
- 241000796654 Axos Species 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 229960000885 rifabutin Drugs 0.000 claims description 4
- 229960001225 rifampicin Drugs 0.000 claims description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 4
- 229960003292 rifamycin Drugs 0.000 claims description 4
- 229960002599 rifapentine Drugs 0.000 claims description 4
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 206010022678 Intestinal infections Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 238000011902 gastrointestinal surgery Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000012487 in-house method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001468213 Amycolatopsis mediterranei Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 101150085857 rpo2 gene Proteins 0.000 description 1
- 101150090202 rpoB gene Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- -1 vitamins D2 and D3 Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
該乳酸菌および/またはビフィズス菌は、他の種に非伝達性である証明された抗生物質耐性を有し、該抗生物質と同じ治療適応症にさらに用いられ;
該組成物は:
(i)グラム陽性およびグラム陰性細菌による急性および慢性腸感染症;
(ii)下痢症候群;
(iii)夏期下痢症、旅行者下痢症および全腸炎より選択される腸内細菌叢の不均衡による下痢;
(iv)消化管手術における感染性合併症の術前および術後予防;
(v)消化管疾患、例えば過敏性腸症候群(IBS)、便秘および腸内細菌叢の変化;
(vi)クローン病および潰瘍性直腸結腸炎を含む慢性炎症性腸疾患(CIID)(炎症性腸疾患(IBD)としても知られる);
(vii)ヘリコバクター・ピロリによる感染症
の治療的処置における使用のためのものである、組成物である。
- 胃液および胆汁酸のバリアを克服し、これにより高い活性(有利な複製のための生細胞および生存細胞)を有して腸に到達するを可能にする、タンパク質マトリックスでコーティングされたビフィドバクテリウム・ロンガム細菌W11 LMG P-21586の株、
- ビフィズス菌増殖(ビフィドジェニック活性)のための特定の栄養素になる結腸に到達するために胃および小腸両方を完全なまま通過することができる、フルクトオリゴ糖、例えばActilight(登録商標)として商業的に知られる製品、またはイヌリン、またはガラクトオリゴ糖GOS、またはキシロオリゴ糖XOS、またはアラビノキシロオリゴ糖AXOSより選択されるプレバイオティック繊維、
- 1以上のB群および/またはD群のビタミン、
- リファマイシン類のグループに属する抗生物質、特にリファキシミン、
- 医薬的に許容される添加剤、香料および安定化剤
を含む。
Claims (10)
- ビフィズス菌の株と組合せて、特定の治療適応症に用いられる抗生物質を含むか、またはそれらからなる、組成物であって;
該ビフィズス菌は、他の種に非伝達性である抗生物質耐性を有し、該抗生物質と同じ治療適応症にも用いられ;
該組成物は:
(i)グラム陽性およびグラム陰性細菌による急性および慢性腸感染症;
(ii)下痢症候群;
(iii)夏期下痢症、旅行者下痢症および全腸炎より選択される腸内細菌叢の不均衡による下痢;
(iv)消化管手術における感染性合併症の術前および術後予防;
(v)消化管疾患、例えば過敏性腸症候群(IBS)、便秘、および腸内細菌叢の変化;
(vi)クローン病および潰瘍性直腸結腸炎を含む慢性炎症性腸疾患(CIID)(炎症性腸疾患(IBD)としても知られる);
(vii)ヘリコバクター・ピロリ(Helicobacter pylori)による感染症
の処置における使用のためのものであり;
該抗生物質は、リファマイシン、リファキシミン、リファンピシン、リファブチンおよびリファペンチンを含むかまたはそれらからなる、群より選択され;
該ビフィズス菌の株は、Belgian Coordinated Collection of Microorganisms(BCCM LMG)に寄託されたビフィドバクテリウム・ロンガム(Bifidobacterium longum)W11(受託番号LMG P-21586)であり、
リファマイシン類のファミリーに属する該抗生物質が、細菌株ビフィドバクテリウム・ロンガムW11 LMG P-21586と同時に投与される、組成物。 - 抗生物質が、リファキシミンである、請求項1に記載の組成物。
- 該組成物が、フルクトオリゴ糖FOS、またはイヌリン、またはガラクトオリゴ糖GOS、またはキシロオリゴ糖XOS、またはアラビノキシロオリゴ糖AXOSより選択されるプレバイオティック繊維をさらに含む、請求項1または2に記載の組成物。
- フルクトオリゴ糖FOSが、一般式GFnを有する、フルクトース(F)分子の鎖に結合したグルコース(G)分子の基本単位からなり、式中nが2〜20の間である、請求項3に記載の組成物。
- nが2〜10の間である、請求項4に記載の組成物。
- 該組成物が、ビタミンB1、B2、B6、B9およびB12より選択されるB群ビタミンおよび/またはビタミンD2およびD3などのD群ビタミンを1つ以上さらに含む、請求項1〜5のいずれか一項に記載の組成物。
- ビフィドバクテリウム・ロンガム細菌W11 LMG P-21586の株が、1グラム当たり1x109〜1x1012の生細胞に含まれる濃度を有する、請求項1〜6のいずれか一項に記載の組成物。
- 該組成物が:
- 1グラム当たり1x109〜1x1012の生細胞に含まれる濃度を有する、タンパク質マトリックスでコーティングされた細菌ビフィドバクテリウム・ロンガムW11 LMG P-21586の株;
- フルクトオリゴ糖FOSまたはガラクトオリゴ糖GOS;
- 1つ以上のB群および/またはD群のビタミン;
- 200 mgの濃度のリファキシミン;ならびに
- 医薬的に許容される添加剤、香料および安定化剤
を含む、請求項1〜7のいずれか一項に記載の組成物。 - 抗生物質と、細菌株ビフィドバクテリウム・ロンガムW11 LMG P-21586が、同一製剤内で完全な混合物として並行投与される、請求項1〜8のいずれか一項に記載の組成物。
- 抗生物質と、細菌株ビフィドバクテリウム・ロンガムW11 LMG P-21586が、互いに短時間内に対象体へ個々に投与される、請求項1〜8のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2015A000624 | 2015-04-30 | ||
ITMI20150624 | 2015-04-30 | ||
PCT/IB2016/052436 WO2016174623A1 (en) | 2015-04-30 | 2016-04-29 | Use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria with a non-transferable antibiotic resistance, having the same therapeutic indication |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018514553A JP2018514553A (ja) | 2018-06-07 |
JP6837992B2 true JP6837992B2 (ja) | 2021-03-03 |
Family
ID=53765303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017556688A Active JP6837992B2 (ja) | 2015-04-30 | 2016-04-29 | 非伝達性の抗生物質耐性を有し、同じ治療適応症を有する乳酸菌および/またはビフィズス菌の同時使用と組合せた、特定の治療活性を有する抗生物質の使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20180125902A1 (ja) |
EP (1) | EP3288554B1 (ja) |
JP (1) | JP6837992B2 (ja) |
KR (1) | KR20180006378A (ja) |
CN (1) | CN107847483A (ja) |
BR (1) | BR112017022823A2 (ja) |
CA (1) | CA2983083A1 (ja) |
DK (1) | DK3288554T3 (ja) |
RU (1) | RU2737891C2 (ja) |
WO (1) | WO2016174623A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2712943C1 (ru) * | 2018-08-03 | 2020-02-03 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы | Способ профилактики туберкулеза при воспалительных заболеваниях кишечника |
CN115074274B (zh) * | 2019-10-14 | 2023-04-18 | 鲁南制药集团股份有限公司 | 含乳酸菌的组合物及其用途 |
WO2024076257A2 (en) | 2022-10-03 | 2024-04-11 | Dikovskiy Alexander Vladimirovich | Composition for treatment of diarrhea of bacterial, viral and bacterial and functional origins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192201A1 (en) * | 1998-09-24 | 2002-12-19 | Ira Shafran | Crohn's disease treatment methods |
ITBO20020564A1 (it) * | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | Bifidobatteri e preparazioni che li contengono. |
WO2011148219A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
US20160206564A1 (en) * | 2013-09-27 | 2016-07-21 | Ira Milton Trachtman | Compositions and methods for treatment and prophylaxis of gastrointestinal diseases |
-
2016
- 2016-04-29 CN CN201680023792.1A patent/CN107847483A/zh active Pending
- 2016-04-29 EP EP16730891.5A patent/EP3288554B1/en active Active
- 2016-04-29 WO PCT/IB2016/052436 patent/WO2016174623A1/en active Application Filing
- 2016-04-29 US US15/569,716 patent/US20180125902A1/en not_active Abandoned
- 2016-04-29 CA CA2983083A patent/CA2983083A1/en not_active Abandoned
- 2016-04-29 RU RU2017139488A patent/RU2737891C2/ru active
- 2016-04-29 KR KR1020177032105A patent/KR20180006378A/ko not_active Application Discontinuation
- 2016-04-29 BR BR112017022823A patent/BR112017022823A2/pt not_active IP Right Cessation
- 2016-04-29 DK DK16730891.5T patent/DK3288554T3/da active
- 2016-04-29 JP JP2017556688A patent/JP6837992B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20180125902A1 (en) | 2018-05-10 |
RU2017139488A (ru) | 2019-05-31 |
RU2737891C2 (ru) | 2020-12-04 |
RU2017139488A3 (ja) | 2019-10-02 |
EP3288554A1 (en) | 2018-03-07 |
BR112017022823A2 (pt) | 2018-07-17 |
CA2983083A1 (en) | 2016-11-03 |
DK3288554T3 (da) | 2022-11-14 |
KR20180006378A (ko) | 2018-01-17 |
JP2018514553A (ja) | 2018-06-07 |
EP3288554B1 (en) | 2022-08-24 |
WO2016174623A1 (en) | 2016-11-03 |
CN107847483A (zh) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101353692B1 (ko) | 프로바이오틱 및 프리바이오틱 성분 및 무기 염을 락토페린과 함께 포함하는 조성물 | |
US20150265661A1 (en) | Prebiotic effect of sialyllactose | |
US20030031659A1 (en) | Probiotic, lactic acid-producing bacteria and uses thereof | |
EP2415475B1 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
JP2004097222A (ja) | ビフィズス菌およびそれを含有する製剤 | |
JP2014531430A (ja) | 胃酸過多の薬物処置中に失われる胃自体の障壁効果を修復することができるプロバイオティック細菌と組み合わされたn−アセチルシステインおよび/またはマイクロカプセル化胃保護型リゾチームを含む組成物 | |
CN102905712A (zh) | 用于治疗肠炎的益生菌组合物 | |
CN114206362A (zh) | 炎性状况和相关感染的治疗方法 | |
JP6837992B2 (ja) | 非伝達性の抗生物質耐性を有し、同じ治療適応症を有する乳酸菌および/またはビフィズス菌の同時使用と組合せた、特定の治療活性を有する抗生物質の使用 | |
US20090136468A1 (en) | Peri-operative composition comprising lactobacillus rhamnosus | |
TWI552685B (zh) | 具有保護腸道益生菌、促進其增生及避免抗生素副作用之功效的大豆發酵益生質之組合物 | |
WO2019069266A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A PROBIOTIC AND PREBIOTIC FOR PREVENTING ACQUISITION OR TREATING OF PHARMACORETISTIVE INFECTIONS | |
TWI819483B (zh) | 乳酸菌組成物及其用於製備抑制抗藥性腸桿菌之口服組成物的用途 | |
KR102685867B1 (ko) | 프로바이오틱 및 프리바이오틱의 조합을 포함하는 약물 저항성 감염의 획득을 예방하거나 치료하기 위한 약학적 조성물 | |
TWI819484B (zh) | 合益素組成物及其用於製備抑制抗藥性腸桿菌之口服組成物的用途 | |
RU2713154C1 (ru) | Антихеликобактерное средство и способ его применения | |
JP2023111825A (ja) | 乳酸菌組成物及び薬剤耐性腸内細菌を抑制するための乳酸菌組成物 | |
CN116515663A (zh) | 乳酸菌组合物及其用于制备抑制抗药性肠杆菌的口服组合物的用途 | |
CN113924107A (zh) | 用于预防单纯性和/或复发性膀胱炎的包含酵母的组合物 | |
BR112020015168A2 (pt) | Composição compreendendo novas cepas de lactobacillus salivarius e método para a prevenção e o tratamento de otite e infecções das vias aéreas superiores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200817 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6837992 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |